OBJECTIVES: To assess the prevalence of, and the variation in, avoidable use of metronidazole in the Veterans Affairs (VA) healthcare system METHODS: Barcode Medication Administration (BCMA) data were retrospectively assessed for all patients hospitalized between January 2006 and December 2010 in acute-care wards of all VA medical centres (VAMCs) with complete BCMA data and at least 10 acute-care non-intensive care unit (ICU) beds. Potentially avoidable metronidazole days of therapy (DOT) were defined as the administration of metronidazole with another anti-anaerobic antibiotic on the same day for at least two consecutive days during the same hospitalization. Metronidazole was not considered redundant in combination with another anti-anaerobic agent within 28 days after a positive test for Clostridium difficile and during hospitalizations associated with discharge diagnosis codes for cholecystitis or cholangitis. RESULTS: A total of 128 VAMCs satisfied the inclusion criteria. Over the study period there were a total of 782,821 DOT of metronidazole (57.4 DOT per 1000 patient-days), of which 183,267 (23.4%) fulfilled the criteria for avoidable metronidazole DOT. The percentage of avoidable metronidazole DOT remained stable over the study period (22.8% in 2006 and 22.9% in 2010) despite a decrease in overall metronidazole use. There was wide variation in the percentage of avoidable metronidazole DOT among facilities (2010: median 20.3%, IQR 15.3%-29.4%). Piperacillin/tazobactam was the most commonly administered drug on avoidable metronidazole DOT (56.8%). CONCLUSIONS: Potentially avoidable use of metronidazole affected about a quarter of all days when metronidazole was given. The combination of metronidazole with piperacillin/tazobactam was particularly common and represents a possible target for antibiotic stewardship interventions.
OBJECTIVES: To assess the prevalence of, and the variation in, avoidable use of metronidazole in the Veterans Affairs (VA) healthcare system METHODS: Barcode Medication Administration (BCMA) data were retrospectively assessed for all patients hospitalized between January 2006 and December 2010 in acute-care wards of all VA medical centres (VAMCs) with complete BCMA data and at least 10 acute-care non-intensive care unit (ICU) beds. Potentially avoidable metronidazole days of therapy (DOT) were defined as the administration of metronidazole with another anti-anaerobic antibiotic on the same day for at least two consecutive days during the same hospitalization. Metronidazole was not considered redundant in combination with another anti-anaerobic agent within 28 days after a positive test for Clostridium difficile and during hospitalizations associated with discharge diagnosis codes for cholecystitis or cholangitis. RESULTS: A total of 128 VAMCs satisfied the inclusion criteria. Over the study period there were a total of 782,821 DOT of metronidazole (57.4 DOT per 1000 patient-days), of which 183,267 (23.4%) fulfilled the criteria for avoidable metronidazole DOT. The percentage of avoidable metronidazole DOT remained stable over the study period (22.8% in 2006 and 22.9% in 2010) despite a decrease in overall metronidazole use. There was wide variation in the percentage of avoidable metronidazole DOT among facilities (2010: median 20.3%, IQR 15.3%-29.4%). Piperacillin/tazobactam was the most commonly administered drug on avoidable metronidazole DOT (56.8%). CONCLUSIONS: Potentially avoidable use of metronidazole affected about a quarter of all days when metronidazole was given. The combination of metronidazole with piperacillin/tazobactam was particularly common and represents a possible target for antibiotic stewardship interventions.
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: Christopher J Graber; Makoto M Jones; Matthew Bidwell Goetz; Karl Madaras-Kelly; Yue Zhang; Jorie M Butler; Charlene Weir; Ann F Chou; Sarah Y Youn; Matthew H Samore; Peter A Glassman Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Gail B Rattinger; C Daniel Mullins; Ilene H Zuckerman; Eberechukwu Onukwugha; Loreen D Walker; Adi Gundlapalli; Matthew Samore; Sylvain Delisle Journal: PLoS One Date: 2012-12-12 Impact factor: 3.240
Authors: Shamshul Ansari; John P Hays; Andrew Kemp; Raymond Okechukwu; Jayaseelan Murugaiyan; Mutshiene Deogratias Ekwanzala; Maria Josefina Ruiz Alvarez; Maneesh Paul-Satyaseela; Chidozie Declan Iwu; Clara Balleste-Delpierre; Ed Septimus; Lawrence Mugisha; Joseph Fadare; Susmita Chaudhuri; Vindana Chibabhai; J M Rohini W W Wadanamby; Ziad Daoud; Yonghong Xiao; Thulasiraman Parkunan; Yara Khalaf; Nkuchia M M'Ikanatha; Maarten B M van Dongen Journal: JAC Antimicrob Resist Date: 2021-04-08
Authors: Young Joo Song; Moonsuk Kim; Saemi Huh; Junghwa Lee; Eunsook Lee; Kyoung-Ho Song; Eu Suk Kim; Hong Bin Kim Journal: Infect Chemother Date: 2015-06-30